Nomura Holdings Inc. Invests $557,000 in Royalty Pharma PLC $RPRX

Key Points

• Nomura Holdings Inc. acquired a new stake of 17,907 shares in Royalty Pharma PLC, valued at approximately $557,000, during the first quarter.
• Royalty Pharma recently declared a quarterly dividend of $0.22 per share, reflecting a 2.4% dividend yield, with a payout ratio of 50.87%.
• Wall Street analysts have a consensus rating of "Buy" for Royalty Pharma, with target prices ranging from $40.00 to $54.00.

Nomura Holdings Inc. bought a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 17,907 shares of the biopharmaceutical company's stock, valued at approximately $557,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Merit Financial Group LLC bought a new position in Royalty Pharma in the 1st quarter worth about $252,000. M&T Bank Corp raised its holdings in Royalty Pharma by 23.4% in the first quarter. M&T Bank Corp now owns 28,967 shares of the biopharmaceutical company's stock worth $902,000 after buying an additional 5,500 shares during the last quarter. Yousif Capital Management LLC bought a new position in shares of Royalty Pharma in the first quarter worth approximately $275,000. Asset Management One Co. Ltd. grew its holdings in shares of Royalty Pharma by 8.0% during the first quarter. Asset Management One Co. Ltd. now owns 164,931 shares of the biopharmaceutical company's stock valued at $5,134,000 after buying an additional 12,148 shares during the last quarter. Finally, Amalgamated Bank lifted its position in Royalty Pharma by 4.4% in the 1st quarter. Amalgamated Bank now owns 20,423 shares of the biopharmaceutical company's stock valued at $636,000 after acquiring an additional 866 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX traded down $0.83 during trading hours on Friday, hitting $36.07. The stock had a trading volume of 9,231,241 shares, compared to its average volume of 3,155,449. The stock has a fifty day moving average price of $36.34 and a 200 day moving average price of $34.19. Royalty Pharma PLC has a 12 month low of $24.05 and a 12 month high of $38.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. The firm has a market capitalization of $21.04 billion, a PE ratio of 20.85, a PEG ratio of 2.35 and a beta of 0.58.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The company had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. Analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 15th. Royalty Pharma's dividend payout ratio (DPR) is currently 50.87%.

Analyst Ratings Changes

RPRX has been the subject of several recent analyst reports. Morgan Stanley boosted their price target on Royalty Pharma from $51.00 to $54.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Citigroup boosted their target price on Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Saturday, August 30th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $48.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.